Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Adam Tomasi Biography and Net Worth

COO of Allakos

Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor relation functions through the company’s initial public offering and sale to AstraZeneca. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and Allakos. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics.

Dr. Tomasi holds a Bachelor of Science in Chemistry from the University of California, Berkeley, an MBA from MIT and a PhD in Chemistry from the University of California, Irvine.

How old is Adam Tomasi?: Dr. Tomasi is currently 54 years old. There are 1 older executives and no younger executives at Allakos. Learn More on Adam Tomasi's age.
How do I contact Adam Tomasi?: The corporate mailing address for Dr. Tomasi and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at [email protected]. Learn More on Adam Tomasi's contact information.
Has Adam Tomasi been buying or selling shares of Allakos?: Adam Tomasi has not been actively trading shares of Allakos over the course of the past ninety days. Most recently, Adam Tomasi sold 20,000 shares of the business's stock in a transaction on Monday, June 14th. The shares were sold at an average price of $91.62, for a transaction totalling $1,832,400.00. Learn More on Adam Tomasi's trading history.
Who are Allakos' active insiders?: Allakos' insider roster includes Robert Alexander (CEO), Peter Hudson (Major Shareholder), Steven James (Director), Daniel Janney (Director), Robert More (Major Shareholder), Henrik Rassmussen (Insider), and Adam Tomasi (COO). Learn More on Allakos' active insiders.

Adam Tomasi Insider Trading History at Allakos

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/14/2021	Sell	20,000	$91.62	$1,832,400.00
6/7/2021	Sell	2,487	$92.03	$228,878.61
6/4/2021	Sell	642	$90.26	$57,946.92
5/11/2021	Sell	20,000	$97.79	$1,955,800.00
4/14/2021	Sell	20,000	$107.77	$2,155,400.00
4/12/2021	Sell	20,000	$104.40	$2,088,000.00
3/9/2021	Sell	20,000	$121.78	$2,435,600.00
3/3/2021	Sell	3,189	$113.56	$362,142.84

Adam Tomasi Buying and Selling Activity at Allakos

Allakos Company Overview

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Today's Range

Now: $1.07

$1.02

$1.09

50 Day Range

MA: $1.29

$1.05

$1.64

2 Week Range

Now: $1.07

$1.00

$5.64

Volume

415,801 shs

Average Volume

1,304,530 shs

Market Capitalization

$94.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82